Understanding the pathogenesis of occupational coal and silica dust-associated lung disease.


Journal

European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391

Informations de publication

Date de publication:
30 Sep 2022
Historique:
received: 09 11 2021
accepted: 20 04 2022
entrez: 13 7 2022
pubmed: 14 7 2022
medline: 16 7 2022
Statut: epublish

Résumé

Workers in the mining and construction industries are at increased risk of respiratory and other diseases as a result of being exposed to harmful levels of airborne particulate matter (PM) for extended periods of time. While clear links have been established between PM exposure and the development of occupational lung disease, the mechanisms are still poorly understood. A greater understanding of how exposures to different levels and types of PM encountered in mining and construction workplaces affect pathophysiological processes in the airways and lungs and result in different forms of occupational lung disease is urgently required. Such information is needed to inform safe exposure limits and monitoring guidelines for different types of PM and development of biomarkers for earlier disease diagnosis. Suspended particles with a 50% cut-off aerodynamic diameter of 10 µm and 2.5 µm are considered biologically active owing to their ability to bypass the upper respiratory tract's defences and penetrate deep into the lung parenchyma, where they induce potentially irreversible damage, impair lung function and reduce the quality of life. Here we review the current understanding of occupational respiratory diseases, including coal worker pneumoconiosis and silicosis, and how PM exposure may affect pathophysiological responses in the airways and lungs. We also highlight the use of experimental models for better understanding these mechanisms of pathogenesis. We outline the urgency for revised dust control strategies, and the need for evidence-based identification of safe level exposures using clinical and experimental studies to better protect workers' health.

Identifiants

pubmed: 35831008
pii: 31/165/210250
doi: 10.1183/16000617.0250-2021
pmc: PMC9724915
pii:
doi:

Substances chimiques

Coal 0
Dust 0
Silicon Dioxide 7631-86-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2022.

Déclaration de conflit d'intérêts

Conflict of interest: No conflict of interest.

Références

Am J Respir Crit Care Med. 2010 Mar 1;181(5):427-8
pubmed: 20185750
J Toxicol Environ Health B Crit Rev. 2006 Sep-Oct;9(5):357-95
pubmed: 16990219
J Med Genet. 2003 Feb;40(2):96-103
pubmed: 12566517
Med J Aust. 2020 Sep;213(6):284-284.e1
pubmed: 32862429
Chemosphere. 2017 Dec;188:32-48
pubmed: 28865791
Respirology. 2017 Feb;22(2):240-250
pubmed: 28102970
J Allergy Clin Immunol. 2019 Jan;143(1):305-315
pubmed: 29857009
Respirology. 2019 Dec;24(12):1165-1175
pubmed: 31517432
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80
pubmed: 9603153
Nat Immunol. 2008 Aug;9(8):847-56
pubmed: 18604214
Multidiscip Respir Med. 2019 Mar 12;14:13
pubmed: 30911386
Part Fibre Toxicol. 2013 Apr 10;10:12
pubmed: 23575443
Am J Respir Crit Care Med. 2017 Aug 1;196(3):283-297
pubmed: 28252317
Free Radic Biol Med. 2008 May 1;44(9):1689-99
pubmed: 18313407
Sci Total Environ. 2020 Jan 10;699:134303
pubmed: 33736201
BMJ Open. 2020 Sep 3;10(9):e038926
pubmed: 32883739
Am J Respir Cell Mol Biol. 2015 Jan;52(1):96-105
pubmed: 24988285
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1178-85
pubmed: 23590267
Ecotoxicol Environ Saf. 2020 Apr 15;193:110364
pubmed: 32114243
Part Fibre Toxicol. 2022 Jan 20;19(1):7
pubmed: 35057792
Environ Health Perspect. 2000 Aug;108 Suppl 4:675-84
pubmed: 10931786
JCI Insight. 2017 Apr 6;2(7):e90443
pubmed: 28405612
Respirology. 2017 May;22(4):662-670
pubmed: 28370783
Respirology. 2014 Aug;19(6):881-90
pubmed: 24831767
Toxicol Appl Pharmacol. 2016 Mar 1;294:11-20
pubmed: 26774687
J Air Waste Manag Assoc. 2015 May;65(5):544-58
pubmed: 25947313
Ind Health. 2015;53(3):260-70
pubmed: 25810444
Mucosal Immunol. 2016 May;9(3):809-20
pubmed: 26509876
Inhal Toxicol. 2000 Jan;12 Suppl 3:225-31
pubmed: 26368620
Environ Toxicol Pharmacol. 2007 Sep;24(2):106-13
pubmed: 21783797
J Occup Environ Med. 2014 Oct;56 Suppl 10:S18-22
pubmed: 25285970
Am J Ind Med. 2018 Jul;61(7):621-624
pubmed: 29732582
Crit Rev Toxicol. 2013 Sep;43(8):632-60
pubmed: 23863112
Chest. 2020 Sep;158(3):1060-1068
pubmed: 32563682
Int J Environ Res Public Health. 2010 Apr;7(4):1773-806
pubmed: 20617059
Int Arch Occup Environ Health. 2017 Jan;90(1):1-12
pubmed: 27628329
Part Fibre Toxicol. 2019 Aug 16;16(1):32
pubmed: 31419990
Thorax. 2015 Dec;70(12):1199-201
pubmed: 26493990
Clin Immunol. 2014 Mar;151(1):1-15
pubmed: 24503171
J Allergy Clin Immunol. 2013 Mar;131(3):752-62
pubmed: 23380220
Curr Environ Health Rep. 2019 Sep;6(3):137-147
pubmed: 31302880
Toxicol Lett. 2021 Dec 15;353:1-12
pubmed: 34626813
Lancet. 2012 May 26;379(9830):2008-18
pubmed: 22534002
Occup Environ Med. 2020 Mar;77(3):142-150
pubmed: 32054818
Lancet Planet Health. 2019 Feb;3(2):e49-e50
pubmed: 30797403
Int J Environ Res Public Health. 2018 Nov 16;15(11):
pubmed: 30453500
Am J Ind Med. 2020 Apr;63(4):337-347
pubmed: 31953962
J Hazard Mater. 2020 Nov 15;399:122935
pubmed: 32540702
Lancet Respir Med. 2019 Oct;7(10):907-920
pubmed: 30975495
Int J Environ Res Public Health. 2013 Aug 27;10(9):3886-907
pubmed: 23985773
Am J Ind Med. 2017 Jun;60(6):513-517
pubmed: 28497853
Environ Health Perspect. 2000 Sep;108(9):841-5
pubmed: 11017888
N Engl J Med. 2017 Jun 29;376(26):2513-2522
pubmed: 28657878
Int J Occup Med Environ Health. 2014 Jan;27(1):78-92
pubmed: 24526496
Front Immunol. 2019 Jan 09;9:3069
pubmed: 30687311
Mol Immunol. 2017 Jun;86:44-55
pubmed: 28129896
PLoS One. 2015 Aug 20;10(8):e0135749
pubmed: 26291610
Environ Int. 2019 Feb;123:543-557
pubmed: 30622079
Chemosphere. 2020 Mar;242:125204
pubmed: 31675579
Am J Public Health. 2018 Sep;108(9):1220-1222
pubmed: 30024799
Redox Biol. 2020 Jul;34:101545
pubmed: 32505541
Respirology. 2006 May;11(3):262-8
pubmed: 16635083
Front Immunol. 2016 Mar 11;7:97
pubmed: 27014276
Environ Health Perspect. 2006 Sep;114(9):1367-73
pubmed: 16966090
Respirology. 2017 May;22(4):634-650
pubmed: 28342288
Exp Cell Res. 2020 Mar 15;388(2):111878
pubmed: 32004504
Respir Med. 2002 Oct;96(10):829-34
pubmed: 12412984
Drug Chem Toxicol. 2000 Feb;23(1):203-22
pubmed: 10711398
Mutat Res. 2005 Dec 30;592(1-2):119-37
pubmed: 16085126
Curr Opin Pulm Med. 2011 Mar;17(2):123-5
pubmed: 21178627
Sci Total Environ. 2018 Jun 1;625:589-599
pubmed: 29291573
Toxicol Lett. 2020 May 1;323:57-66
pubmed: 32017981
Am J Epidemiol. 2017 Oct 15;186(8):961-969
pubmed: 28541385
JCI Insight. 2019 Jul 25;5:
pubmed: 31343988
Science. 2005 May 6;308(5723):804-6
pubmed: 15879201
Regul Toxicol Pharmacol. 2020 Apr;112:104618
pubmed: 32087352
Int J Tuberc Lung Dis. 2007 May;11(5):474-84
pubmed: 17439668
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
Med J Aust. 2016 Jun 20;204(11):414-8
pubmed: 27318401
Environ Res. 2019 Feb;169:237-245
pubmed: 30476747
Biomed Pharmacother. 2019 Nov;119:109387
pubmed: 31487583
Mutat Res Genet Toxicol Environ Mutagen. 2014 Mar 1;762:24-9
pubmed: 24525377
JCI Insight. 2016 Jun 16;1(9):
pubmed: 27398409
Allergy. 2020 Nov;75(11):2805-2817
pubmed: 31989662
Ecotoxicol Environ Saf. 2018 Dec 15;165:44-51
pubmed: 30179764
J Med Imaging Radiat Oncol. 2020 Apr;64(2):229-235
pubmed: 32048474
Mucosal Immunol. 2020 Nov;13(6):877-891
pubmed: 32820248
Ind Health. 2019 Aug 3;57(4):495-502
pubmed: 30344228
J Med Case Rep. 2008 Aug 05;2:257
pubmed: 18681950
Toxicology. 2009 Jun 30;261(1-2):1-8
pubmed: 19379789
Occup Environ Med. 2011 Dec;68(12):908-13
pubmed: 21597107
Front Pharmacol. 2020 Mar 18;11:301
pubmed: 32256366
Biomed Pharmacother. 2020 Jan;121:109586
pubmed: 31706104
Part Fibre Toxicol. 2013 Dec 19;10:63
pubmed: 24354623
Front Immunol. 2020 Feb 18;11:219
pubmed: 32133004
Curr Med Sci. 2019 Aug;39(4):551-559
pubmed: 31346990
Environ Res. 2004 Nov;96(3):290-7
pubmed: 15364596
Chest. 2019 Feb;155(2):417-426
pubmed: 30419237
J Toxicol Environ Health B Crit Rev. 2006 Jan-Feb;9(1):27-39
pubmed: 16393868

Auteurs

Kanth Swaroop Vanka (KS)

School of Biomedical Sciences and Pharmacy, The University of Newcastle/Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.
Division of Pulmonary, Allergy, and Critical Care Medicine, Dept of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lung Biology Institute, University of Pennsylvania, Philadelphia, PA, USA.

Shakti Shukla (S)

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Henry M Gomez (HM)

School of Biomedical Sciences and Pharmacy, The University of Newcastle/Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.

Carole James (C)

School of Health Sciences, The University of Newcastle, Newcastle, NSW, Australia.

Thava Palanisami (T)

Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment (CERSE), The University of Newcastle, Newcastle, NSW, Australia.

Kenneth Williams (K)

Newcastle Institute for Energy and Resources (NIER), School of Engineering, The University of Newcastle, Newcastle, NSW, Australia.

Daniel C Chambers (DC)

School of Clinical Medicine, The University of Queensland, Brisbane, QLD, Australia.
Queensland Lung Transplant Program, The Prince Charles Hospital, Brisbane, QLD, Australia.

Warwick J Britton (WJ)

Centenary Institute, The University of Sydney, Sydney, NSW, Australia.
Dept of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

Dusan Ilic (D)

Newcastle Institute for Energy and Resources (NIER), School of Engineering, The University of Newcastle, Newcastle, NSW, Australia.

Philip Michael Hansbro (PM)

School of Biomedical Sciences and Pharmacy, The University of Newcastle/Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia.
Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia.
School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
P.M. Hansbro and J.C. Horvat have equally contributed as senior authors.

Jay Christopher Horvat (JC)

School of Biomedical Sciences and Pharmacy, The University of Newcastle/Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia jay.horvat@newcastle.edu.
P.M. Hansbro and J.C. Horvat have equally contributed as senior authors.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH